In vitro aerosol characterization of Staccato(®) Loxapine.
Medicinal aerosol products (metered dose and dry powder inhalers) require characterization testing over a wide range of use and pre-operating stress scenarios in order to ensure robust product performance and support submissions for regulatory approval. Aerosol characterization experiments on Staccato(®) Loxapine for inhalation (Staccato Loxapine) product (emitted dose, particle size, and purity) were assessed at different operating settings (flow rates, ambient temperature and humidity, altitude, and orientation) and at nominal test conditions following exposure to various stresses on the device (mechanical shock, vibration, drop, thermal cycling, and light exposure). Emitted dose values were approximately 90% of the coated dose at every condition, meeting target specifications in each case. Aerosol purity was consistently >99.5% for every test setting, with no reportable impurities according to ICH standards (>0.1%). Particle size averaged 2μm (MMAD) and was independent of the different test conditions with the exception of different airflow rates. Particle size decreased slightly with airflow, which may assist in maintaining constant deep lung deposition. The combination of high emitted dose efficiency and a particle size range ideally suited for lung deposition, along with the consistency of these key aerosol attributes, suggests that the Staccato system has distinct advantages over more traditional aerosol systems.
Alexza Pharmaceuticals, Mountain View, CA 94043, USA.
Khe
K
Dinh
Dan J
DJ
Myers
Marc
M
Glazer
Tamara
T
Shmidt
Caitlin
C
Devereaux
Kathleen
K
Simis
Peter D
PD
Noymer
Min
M
He
Corinna
C
Choosakul
Qiang
Q
Chen
James V
JV
Cassella
D000336:Aerosols; D002851:Chromatography, High Pressure Liquid; D004867:Equipment Design; D006813:Humidity; D008152:Loxapine / Q000008:administration & dosage / Q000737:chemistry*; D036501:Metered Dose Inhalers; D010316:Particle Size
D000336:Aerosols; D008152:Loxapine